

> 定義 and 流行病學 (Lancet 2017;389:1931)


# CHRONIC OBSTRUCTIVE PULMONARY DISEASE

## 定義 and 流行病學 (_Lancet_ 2017;389:1931)

• Progressive airflow limitation caused by airway and parenchymal inflammation

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Emphysema vs. Chronic Bronchitis</b></p></td></tr><tr><td></td><td><p>Emphysema</p></td><td><p>Chronic Bronchitis</p></td></tr><tr><td><p><b>定義</b></p></td><td><p>Dilation/destruction of parenchyma (path 定義)</p></td><td><p>Productive cough &gt;3 mo/y × ≥2 y (臨床定義)</p></td></tr><tr><td><p><b>病生理</b></p></td><td><p>Tissue destruction</p><p>V/Q: ↑ dead space fraction → hypercarbia, but only mild hypoxemia</p></td><td><p>Small airways affected V/Q: ↑ shunt fraction → severe hypoxemia, hypercapnia PHT, cor pulmonale</p></td></tr><tr><td><p><b>臨床表現</b></p></td><td><p>Severe, constant dyspnea</p><p>Mild cough</p></td><td><p>Intermittent dyspnea</p><p>Copious sputum production</p></td></tr><tr><td><p><b>Physical exam</b></p></td><td><p>“Pink puffer”</p><p>Tachypneic, noncyanotic, thin</p><p>Diminished breath sounds</p></td><td><p>“Blue bloater”</p><p>Cyanotic, obese, edematous</p><p>Rhonchi &amp; wheezes</p></td></tr></tbody></table>

## Pathogenesis (_Lancet_ 2017;389:1931)

• **Cigarette smoke** (centrilobular emphysema, affects 15–20% of smokers)

• Recurrent airway infections

• α1\-antitrypsin deficiency: early-onset panacinar emphysema, 1–3% of COPD cases. Suspect if age <45, lower lungs affected, extrathoracic 表現 (liver disease \[not if MZ subtype\], FMD, pancreatitis). ✔ serum AAT level (nb, acute phase reactant).

• Low FEV1 in early adulthood associated with COPD (_NEJM_ 2015;373:111)

## 臨床表現

• Chronic cough, sputum production, dyspnea; later stages → freq exacerb, AM HA, wt loss

• Exacerbation triggers: infxn, other cardiopulmonary disease, including PE

Infxn: overt tracheobronchitis/pneumonia from viruses, _S. pneumoniae_, _H. influenzae_, _M. catarrhalis_ or triggered by changes in strain of colonizers (_NEJM_ 2008;359:2355)

• Physical exam: ↑ AP diameter of chest (“barrel chest”), hyperresonance, ↓ diaphragmatic

excursion, ↓ breath sounds, ↑ expiratory phase, rhonchi, wheezes

during exacerbation: tachypnea, accessory muscle use, pulsus paradoxus, cyanosis

• _Asthma-COPD overlap syndrome_ (ACOS; _NEJM_ 2015;373:1241): features of both present. For example: reversibility of airway obstruction with bronchodilator in COPD; neutrophilic inflammation in asthma (more classic in COPD); eos in COPD

## Diagnostic studies (_JAMA_ 2019;321:786)

• CXR (see Radiology inserts): hyperinflation, flat diaphragms, ± interstitial markings & bullae

• 肺功能: **obstruction:** ↓↓ FEV1, ↓ FVC, **FEV1/FVC** <**0.7 (no sig** Δ **post bronchodilator)**, expiratory scooping of flow-volume loop; **hyperinflation:** ↑↑ RV, ↑ TLC, ↑ RV/TLC;

**abnormal gas exchange:** ↓ DLCO (in emphysema)

• ABG: ↓ PaO2, ± ↑ PaCO2 (in chronic bronchitis, usually only if FEV1 <1.5 L) and ↓ pH

• Screen _symptomatic_ 病人 with spirometry; don’t screen if asx; screen for α1-AT deficiency

## Chronic 治療 (_JAMA_ 2019;321:786)

• **Bronchodilators** (_1__st__\-line_): **long-acting muscarinic antag (LAMA)**, β2\-agonists (LABA)

LAMA (eg, tiotropium): ↓ exacerb, slows ↓ FEV1, ↓ admit, ↓ resp failure; better than ipratropium or LABA (_NEJM_ 2008;359:1543; 2011;364:1093; 2017;377:923)

LABA: ~11% ↓ in exacerbations, no ↑ in CV events (_Lancet_ 2016;387:1817)

LAMA + LABA: ↑ FEV1, ↓ sx vs. either alone (_Chest_ 2014;145:981) and superior to LABA + inh steroid (_NEJM_ 2016;374:2222)

• **Corticosteroids** (inhaled, ICS): ~11% ↓ in exacerbations & slows ↓ FEV1; no Δ in risk of PNA or in mortality (_Lancet_ 2016;387:1817)

• “Triple Therapy” (ICS-LAMA-LABA) ↓ exac, ↓ hosp, ↑ PNA (_Lancet_ 2016;388:963 & 2018;391:1076; _NEJM_ 2018; 378:1671)

• Roflumilast (PDE-4 inhib) + bronchodil: ↑ FEV1, ↓ exacerb (_Lancet_ 2015;385:857)

• Anti-IL5 (eg, mepolizumab, benralizumab): mixed data on ↓ exacerb in 病人 with eos (_NEJM_ 2017;377:1613 & 2019;DOI:10.1056/NEJMoa1905248)

• Antibiotics: daily azithro ↓ exacerbations, but not routine (_JAMA_ 2014;311:2225)

• **Oxygen:** if PaO2 ≤55 mmHg or SaO2 ≤89% (during rest, exercise, or sleep) to prevent cor

pulmonale; only Rx proven to ↓ mortality (_Annals_ 1980;93:391; _Lancet_ 1981;i:681); no benefit in 病人 with moderate hypoxemia (SaO2 89–93%) (_NEJM_ 2016;375:1617)

• NPPV if recent exacerb & PaCO2 >53 ↓ risk of readmit or death (_JAMA_ 2017;317:2177)

• **Prevention:** Flu/Pneumovax; smoking cessation → 50% ↓ in lung function decline (_AJRCCM_ 2002;166:675) and ↓ long-term mortality (_Annals_ 2005;142:223)

• Rehabilitation: ↓ dyspnea and fatigue, ↑ exercise tolerance, ↓ 生活品質 (_NEJM_ 2009;360:1329)

• Surgery & bronchoscopic interventions

Lung volume reduction surgery: ↑ exercise capacity, ↓ mortality _if_ FEV1 >20%, upper lobe, low exercise capacity (_NEJM_ 2003;348:2059)

Bronchoscopic lung reduction with endobronchial valves or coils: ↑ lung fxn but significant complications (PTX, PNA) (_NEJM_ 2015;373:2325; _Lancet_ 2015;386:1066; _JAMA_ 2016;315175)

• Lung transplant: ↑ 生活品質 and ↓ sx (_Lancet_ 1998;351:24), ? survival benefit (_Am J Transplant_ 2009;9:1640)

## Staging and prognosis

• Assess breathlessness, cough, sputum, exercise capacity & energy (tools such as CAT and mMRC may be used as part of assessment)

• Ratio of diam PA/aorta >1 associated with ~3× ↑ risk of exacerbations (_NEJM_ 2012;367:913)

![](https://i.imgur.com/1CmPMb5.jpg)

Smoking cessation & vaccinations in all. Pulm rehab in groups B–D. O2 as indicated per SaO2. (Adapted from GOLD Executive Summary \[_AJRCCM_ 2017;195:557\])

## EXACERBATION

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>COPD Exacerbation 治療</b></p></td></tr><tr><td><p>Agent</p></td><td><p>Dose</p></td><td><p>Comments</p></td></tr><tr><td><p><b>Ipratropium</b></p></td><td><p>MDI 4–8 puffs q1–2h <i>or</i></p><p>Nebulizer 0.5 mg q1–2h</p></td><td><p>First-line therapy (<span><i>NEJM</i> 2011;364:1093</span>)</p></td></tr><tr><td><p><b>Albuterol</b></p></td><td><p>MDI 4–8 puffs q1–2h <i>or</i></p><p>Nebulizer 2.5–5 mg q1–2h</p></td><td><p>Benefit if component of reversible bronchoconstriction</p></td></tr><tr><td><p><b>Corticosteroids</b></p></td><td><p>Prednisone 40 mg/d × 5d (<span><i>JAMA</i> 2013;309:2223</span>); some 病人 will benefit from higher dose/longer course if severe</p><p>Methylprednisolone 125 mg IV q6h × 72 h for more severe exacerbations</p></td><td><p>↓ 治療 failure, ↓ hosp. stay</p><p>↑ FEV<sub>1</sub> but no mortality benefit,</p><p>↑ complications (<span><i>Cochrane</i> 2009:CD001288</span>)</p><p>OutPt Rx after ED visit ↓ relapse (<span><i>NEJM</i> 2003;348:2618</span>)</p></td></tr><tr><td><p><b>Antibiotics</b></p></td><td><p>Amox, TMP-SMX, doxy, clarithro, antipneumococcal FQ all reasonable (no single 抗生素 proven superior). Consider local flora and avoid repeat courses of same 抗生素. ≤5d course likely enough for mild-mod exacerbation (<span><i>JAMA</i> 2010;303:2035</span>).</p></td><td><p><i>H. flu</i>, <i>M. catarrhalis</i>, <i>S. pneumo</i></p><p>↑ PEF, ↓ Rx failure, ? ↓ short-term mort, ↓ subseq exacerb (<span><i>Chest</i> 2008;133:756 &amp; 2013;143:82</span>)</p><p>Consider if ↑ sputum purulence or CRP &gt;40 (<span><i>Chest</i> 2013;144:1571</span>)</p></td></tr><tr><td><p><b>Oxygenation</b></p></td><td><p>↑ F<sub>i</sub>O<sub>2</sub> to achieve P<sub>a</sub>O<sub>2</sub> ≥55–60 <i>or</i> S<sub>a</sub>O<sub>2</sub> 90–93%</p></td><td><p><b>Watch for CO<sub>2</sub> retention</b> (due to ↑ V/Q mismatch, loss of hypoxemic resp drive, Haldane effect) <i>but must maintain oxygenation!</i></p></td></tr><tr><td><p><b>Noninvasive positive-pressure ventilation</b></p></td><td colspan="2"><p>Initiate <i>early</i> if moderate/severe dyspnea, ↓ pH / ↑ P<sub>a</sub>CO<sub>2</sub>, RR &gt;25</p><p>Results in 58% ↓ intubation, ↓ LOS by 3.2 d, 59% ↓ mortality</p><p>Contraindications: Δ MS, inability to cooperate or clear secretions, hemodynamic instability, UGIB</p><p>(<span><i>NEJM</i> 1995;333:817; <i>Annals</i> 2003;138:861; <i>Cochrane</i> 2004;CD004104; <i>ERJ</i> 2005;25:348</span>)</p></td></tr><tr><td><p><b>Endotracheal intubation</b></p></td><td colspan="2"><p>Consider if P<sub>a</sub>O<sub>2</sub> &lt;55–60, ↑‘ing P<sub>a</sub>CO<sub>2</sub>, ↓‘ing pH, ↑ RR, respiratory</p><p>fatigue, Δ MS or hemodynamic instability</p></td></tr><tr><td><p><b>Other measures</b></p></td><td colspan="2"><p>Mucolytics overall not supported by data (<span><i>Chest</i> 2001;119:1190</span>)</p><p>Monitor for cardiac arrhythmias</p></td></tr><tr><td><p><b>Post-exacerb care</b></p></td><td colspan="2"><p>Follow up within 1 mo; smoking cessation if current smoker; vaccinations (influenza, pneumococcal), referral to pulm rehab (<span><i>AJRCCM</i> 2007;176:532</span>)</p></td></tr></tbody></table>
